PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33585999-3	2021	We aimed to identify the recommended phase 2 dose (RP2D) of ruxolitinib in combination with paclitaxel in patients with HER2-negative metastatic breast cancer (MBC).	ruxolitinib	60-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124	
31681603-6	2019	Silencing the identified alternative proteins via siRNA resulted in significant drop in the LC50 of the selected molecularly-targeted drugs cells resistant to ruxolitinib (via targeting Akt), everolimus (via targeting EGFR, MAPK7, RPS6KA5, and HER2), and erlotinib (via silencing Bcl2 and BIRC8).	ruxolitinib	159-170	erb-b2 receptor tyrosine kinase 2	Homo sapiens	244-248	
29436642-0	2018	Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive, human epidermal growth factor receptor 2-positive breast cancer cells.	ruxolitinib	34-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-132	
29436642-11	2018	The results of the present study demonstrated the synergistic anticancer effects of ruxolitinib and calcitriol in ER and HER2-positive MCF7-HER18 breast cancer cells.	ruxolitinib	84-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125	
34169393-0	2021	Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.	ruxolitinib	20-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82	
34169393-3	2021	We performed a phase I/II trial investigating the safety and efficacy of the combination of trastuzumab and ruxolitinib in patients with trastuzumab-resistant metastatic HER2+ breast cancer.	ruxolitinib	108-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	170-174	
29675680-0	2018	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.	ruxolitinib	45-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131	
29675680-2	2018	This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhibitor, to capecitabine in patients with HER2-negative advanced breast cancer and high systemic inflammation (modified Glasgow Prognostic Score [mGPS] >= 1).	ruxolitinib	83-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-156	
33585999-0	2021	Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.	ruxolitinib	34-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94